INTRODUCTION: Avian H5N1 influenza viruses currently circulating in southeast Asia could potentially cause the next pandemic. However, currently licensed human vaccines are subtype-specific and do not protect against these H5N1 viruses. We aimed to develop an influenza vaccine and assessed its immunogenicity and efficacy to confer protection in BALB/c mice. METHODS: We developed an egg-independent strategy to combat the avian influenza virus, because the virus is highly lethal to chickens and the maintenance of a constant supply of embryonated eggs would be difficult in a pandemic. We used a replication-incompetent, human adenoviral-vector-based, haemagglutinin subtype 5 influenza vaccine (HAd-H5HA), which induces both humoral and cell-mediated immune responses against avian H5N1 influenza viruses isolated from people. FINDINGS: Immunisation of mice with HAd-H5HA provided effective protection from H5N1 disease, death, and primary viral replication (p<0.0001) against antigenically distinct strains of H5N1 influenza viruses. Unlike the recombinant H5HA vaccine, which is based on a traditional subunit vaccine approach, HAd-H5HA vaccine induced a three-fold to eight-fold increase in HA-518-epitope-specific interferon-gamma-secreting CD8 T cells (p=0.01). INTERPRETATION: Our findings highlight the potential of an Ad-vector-based delivery system, which is both egg-independent and adjuvant-independent and offers stockpiling options for the development of a pandemic influenza vaccine.
INTRODUCTION: Avian H5N1 influenza viruses currently circulating in southeast Asia could potentially cause the next pandemic. However, currently licensed human vaccines are subtype-specific and do not protect against these H5N1 viruses. We aimed to develop an influenza vaccine and assessed its immunogenicity and efficacy to confer protection in BALB/c mice. METHODS: We developed an egg-independent strategy to combat the avian influenza virus, because the virus is highly lethal to chickens and the maintenance of a constant supply of embryonated eggs would be difficult in a pandemic. We used a replication-incompetent, human adenoviral-vector-based, haemagglutinin subtype 5 influenza vaccine (HAd-H5HA), which induces both humoral and cell-mediated immune responses against avian H5N1 influenza viruses isolated from people. FINDINGS: Immunisation of mice with HAd-H5HA provided effective protection from H5N1 disease, death, and primary viral replication (p<0.0001) against antigenically distinct strains of H5N1 influenza viruses. Unlike the recombinant H5HA vaccine, which is based on a traditional subunit vaccine approach, HAd-H5HA vaccine induced a three-fold to eight-fold increase in HA-518-epitope-specific interferon-gamma-secreting CD8 T cells (p=0.01). INTERPRETATION: Our findings highlight the potential of an Ad-vector-based delivery system, which is both egg-independent and adjuvant-independent and offers stockpiling options for the development of a pandemic influenza vaccine.
Authors: J J Treanor; B E Wilkinson; F Masseoud; J Hu-Primmer; R Battaglia; D O'Brien; M Wolff; G Rabinovich; W Blackwelder; J M Katz Journal: Vaccine Date: 2001-02-08 Impact factor: 3.641
Authors: S Sambhara; A Kurichh; R Miranda; T Tumpey; T Rowe; M Renshaw; R Arpino; A Tamane; A Kandil; O James; B Underdown; M Klein; J Katz; D Burt Journal: Cell Immunol Date: 2001-08-01 Impact factor: 4.868
Authors: R J Webby; D R Perez; J S Coleman; Y Guan; J H Knight; E A Govorkova; L R McClain-Moss; J S Peiris; J E Rehg; E I Tuomanen; R G Webster Journal: Lancet Date: 2004-04-03 Impact factor: 79.321
Authors: J S M Peiris; W C Yu; C W Leung; C Y Cheung; W F Ng; J M Nicholls; T K Ng; K H Chan; S T Lai; W L Lim; K Y Yuen; Y Guan Journal: Lancet Date: 2004-02-21 Impact factor: 79.321
Authors: Haroldo Toro; De-chu C Tang; David L Suarez; Matt J Sylte; Jennifer Pfeiffer; Kent R Van Kampen Journal: Vaccine Date: 2006-09-25 Impact factor: 3.641
Authors: M A Hoelscher; L Jayashankar; S Garg; V Veguilla; X Lu; N Singh; J M Katz; S K Mittal; S Sambhara Journal: Clin Pharmacol Ther Date: 2007-10-24 Impact factor: 6.875
Authors: Leo L M Poon; Y H Connie Leung; John M Nicholls; Pin-Yu Perera; Jack H Lichy; Masafumi Yamamoto; Thomas A Waldmann; J S Malik Peiris; Liyanage P Perera Journal: J Immunol Date: 2009-03-01 Impact factor: 5.422